Adicet Bio Announces Inducement Grant

09/30/2025 – 04:27 PM

REDWOOD CITY, Calif. & BOSTON – Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology firm focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced today the grant of an inducement award, effective September 30, 2025.

According to the company’s statement, one individual joining Adicet in September 2025 received a non-qualified stock option to purchase 9,800 shares of the company’s common stock. The exercise price was set at $0.81 per share, mirroring the closing price of Adicet’s common stock on Nasdaq on the same date.

The vesting schedule for these options is structured with a one-year cliff, where one-fourth of the shares vest on the first anniversary of the employee’s start date. Subsequently, the remaining three-fourths vest in 36 equal monthly installments. This means the options will be fully vested on the fourth anniversary of the employee’s start date, contingent upon continued employment with Adicet. This vesting schedule is standard practice in the biotech industry, designed to incentivize long-term commitment and alignment with the company’s success.

The inducement award, as the company notes, falls outside Adicet’s existing stockholder-approved equity incentive plans. Instead, it was granted under the 2022 Inducement Plan, adopted by the board of directors in January 2022 and amended in January 2023. It’s crucial to note the compensation committee, comprising solely independent directors, authorized this award as a material incentive for the new hire, adhering to Nasdaq Listing Rule 5635(c)(4). This approach is designed to ensure independence and prevent undue influence during compensation decisions, a key governance principle in publicly traded companies.

The use of inducement grants is a common tactic among companies, particularly in high-growth sectors like biotechnology. It allows them to attract key talent without depleting the pool of shares allocated under broader employee equity plans. However, investors often scrutinize these grants, assessing whether they are proportional to the employee’s expected contribution and aligned with shareholder interests. Any perceived misalignment can lead to investor concern about potential overcompensation and dilution.

About Adicet Bio, Inc.

Adicet Bio, Inc. is dedicated to the discovery and development of allogeneic gamma delta T cell therapies. Their approach centers around “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs). The promise is to deliver durable therapeutic activity for patients facing autoimmune diseases and cancers. For more information, please visit https://www.adicetbio.com.